Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Furaprevir and Yimitasvir in Healthy Chinese Volunteers
NCT03610880Phase 1Completed
- Sponsor
- Dongguan HEC TaiGen Biopharmaceuticals
- Start
- Oct 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in hepatitis C (HCV) comparing Furaprevir -> Combination with Yimitasvir -> Combination (2 arms). Primary endpoints: Maximum Plasma Concentration at Steady State at 14 weeks, Trough Plasma Concentration at Steady State at 14 weeks and 1 more. Started Oct 2017; status: completed.
02
Drugs
furapreviryimitasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03610880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03610880.